Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Cash from Operations (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Cash from Operations for 13 consecutive years, with 6508000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations fell 25.25% to 6508000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 243703000.0, a 1215.14% increase, with the full-year FY2024 number at 11535000.0, up 57.27% from a year prior.
  • Cash from Operations was 6508000.0 for Q3 2025 at Theravance Biopharma, down from 208074000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 208074000.0 in Q2 2025 to a low of 69865000.0 in Q1 2021.
  • A 5-year average of 11504538.46 and a median of 5196000.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: decreased 26.79% in 2021, then surged 4812.89% in 2025.
  • Theravance Biopharma's Cash from Operations stood at 69865000.0 in 2021, then soared by 178.6% to 54913000.0 in 2022, then tumbled by 120.43% to 11221000.0 in 2023, then soared by 91.96% to 902000.0 in 2024, then crashed by 621.51% to 6508000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Cash from Operations are 6508000.0 (Q3 2025), 208074000.0 (Q2 2025), and 43039000.0 (Q1 2025).